NK cells and cancer: you can teach innate cells new tricks

Key Points Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. A balance of inhibitory and stimulatory signals delivered by numerous receptors...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Cancer 2016-01, Vol.16 (1), p.7-19
Hauptverfasser: Morvan, Maelig G., Lanier, Lewis L.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 19
container_issue 1
container_start_page 7
container_title Nature reviews. Cancer
container_volume 16
creator Morvan, Maelig G.
Lanier, Lewis L.
description Key Points Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. A balance of inhibitory and stimulatory signals delivered by numerous receptors regulates NK cell functions (cytotoxicity, cytokine production and proliferation). NKG2D is the best characterized of these activating receptors and is directly involved in the recognition of tumours that express NKG2D ligands. NK cells detect and eliminate tumour cells that are deficient in major histocompatibility complex (MHC) class I molecules (missing self), have upregulated stress ligands that are recognized by activating NK cell receptors (induced self), or are coated with antibodies specific for tumour antigens, enabling recognition by NK cells expressing the CD16 Fc receptor, which triggers antibody-dependent cell-mediated cytotoxicity. Immunoediting of tumour cells by NK cells leads to tumour variants that can evade NK cell-mediated responses. Direct and indirect tumour escape mechanisms include secretion of immunosuppressive factors, shedding of ligands for the activating NK cell receptors and induction of ligands for activating NK cell receptors on healthy cells that can serve as decoys. Current checkpoint blockade agents used to activate T cells in cancer patients, such as antibodies against PD1, may also target NK cells. Checkpoint blockade targeting inhibitory receptors shared by NK cells and T cells are currently under clinical evaluation. In addition to engineered T cells, NK cells and their receptors represent an attractive alternative for the use of chimeric antigen receptors. Immunotherapeutic approaches such as the generation of bispecific linkers that engage activating NK cell receptors and tumour-specific antigens are also being developed to unleash the antitumour potential of NK cells. This Review discusses the role of natural killer (NK) cells in immunosurveillance of tumour cells, highlighting the new therapeutic approaches to NK cell targeting in the treatment of cancer and improvement of NK cell-mediated antitumour immune responses. Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for t
doi_str_mv 10.1038/nrc.2015.5
format Article
fullrecord <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_1773836796</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A439361815</galeid><sourcerecordid>A439361815</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-db8322d9962fd5752d807ef0a683407ff5078afa46a58519c44bf0c0a492c28f3</originalsourceid><addsrcrecordid>eNqN0VtLBCEUB3CJovtLHyAGgohiN-86vUV0o6iXgt7EdbSdmtXSGaJvn8NusV0ewgdFf-fg4Q_AFoJDBIk89NEMMURsyBbAKqKCDpDgcvHrzB5WwFpKTxAijgRaBiuY85KWhK2Co5urwtimSYX2VWG0NzYeFe-h689Fa7UZF7X3urUz5u1b0cbaPKcNsOR0k-zmbF8H92endycXg-vb88uT4-uBYUi2g2okCcZVWXLsKiYYriQU1kHNJaFQOMegkNppyjWTDJWG0pGDBmpaYoOlI-tgb9r3JYbXzqZWTerUf0Z7G7qkkBBEEi5K_g_KUB6dQ5zpzg_6FLro8yBZcUEoxnROPerGqtq70EZt-qbqmJKScCQRy2r4h8qrspPaBG9dne-_FezOFYytbtpxCk3X1sGn73B_Ck0MKUXr1EusJzq-KwRVH77K4as-fNXj7dlI3Whiqy_6mXYGB1OQ8pN_tHFu5t_tPgDvBbKr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1767342242</pqid></control><display><type>article</type><title>NK cells and cancer: you can teach innate cells new tricks</title><source>MEDLINE</source><source>Nature Journals Online</source><source>SpringerLink Journals - AutoHoldings</source><creator>Morvan, Maelig G. ; Lanier, Lewis L.</creator><creatorcontrib>Morvan, Maelig G. ; Lanier, Lewis L.</creatorcontrib><description>Key Points Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. A balance of inhibitory and stimulatory signals delivered by numerous receptors regulates NK cell functions (cytotoxicity, cytokine production and proliferation). NKG2D is the best characterized of these activating receptors and is directly involved in the recognition of tumours that express NKG2D ligands. NK cells detect and eliminate tumour cells that are deficient in major histocompatibility complex (MHC) class I molecules (missing self), have upregulated stress ligands that are recognized by activating NK cell receptors (induced self), or are coated with antibodies specific for tumour antigens, enabling recognition by NK cells expressing the CD16 Fc receptor, which triggers antibody-dependent cell-mediated cytotoxicity. Immunoediting of tumour cells by NK cells leads to tumour variants that can evade NK cell-mediated responses. Direct and indirect tumour escape mechanisms include secretion of immunosuppressive factors, shedding of ligands for the activating NK cell receptors and induction of ligands for activating NK cell receptors on healthy cells that can serve as decoys. Current checkpoint blockade agents used to activate T cells in cancer patients, such as antibodies against PD1, may also target NK cells. Checkpoint blockade targeting inhibitory receptors shared by NK cells and T cells are currently under clinical evaluation. In addition to engineered T cells, NK cells and their receptors represent an attractive alternative for the use of chimeric antigen receptors. Immunotherapeutic approaches such as the generation of bispecific linkers that engage activating NK cell receptors and tumour-specific antigens are also being developed to unleash the antitumour potential of NK cells. This Review discusses the role of natural killer (NK) cells in immunosurveillance of tumour cells, highlighting the new therapeutic approaches to NK cell targeting in the treatment of cancer and improvement of NK cell-mediated antitumour immune responses. Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.</description><identifier>ISSN: 1474-175X</identifier><identifier>EISSN: 1474-1768</identifier><identifier>DOI: 10.1038/nrc.2015.5</identifier><identifier>PMID: 26694935</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/1619/382 ; 631/67/1059/2325 ; 631/67/327 ; Biomedicine ; Cancer ; Cancer Research ; Care and treatment ; Health aspects ; Humans ; Immune response ; Killer cells ; Killer Cells, Natural - physiology ; Ligands ; Neoplasms - immunology ; Neoplasms - pathology ; Neoplasms - therapy ; Receptors, Natural Killer Cell - physiology ; Regulation ; review-article</subject><ispartof>Nature reviews. Cancer, 2016-01, Vol.16 (1), p.7-19</ispartof><rights>Springer Nature Limited 2016</rights><rights>COPYRIGHT 2016 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jan 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-db8322d9962fd5752d807ef0a683407ff5078afa46a58519c44bf0c0a492c28f3</citedby><cites>FETCH-LOGICAL-c518t-db8322d9962fd5752d807ef0a683407ff5078afa46a58519c44bf0c0a492c28f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrc.2015.5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrc.2015.5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,41487,42556,51318</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26694935$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morvan, Maelig G.</creatorcontrib><creatorcontrib>Lanier, Lewis L.</creatorcontrib><title>NK cells and cancer: you can teach innate cells new tricks</title><title>Nature reviews. Cancer</title><addtitle>Nat Rev Cancer</addtitle><addtitle>Nat Rev Cancer</addtitle><description>Key Points Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. A balance of inhibitory and stimulatory signals delivered by numerous receptors regulates NK cell functions (cytotoxicity, cytokine production and proliferation). NKG2D is the best characterized of these activating receptors and is directly involved in the recognition of tumours that express NKG2D ligands. NK cells detect and eliminate tumour cells that are deficient in major histocompatibility complex (MHC) class I molecules (missing self), have upregulated stress ligands that are recognized by activating NK cell receptors (induced self), or are coated with antibodies specific for tumour antigens, enabling recognition by NK cells expressing the CD16 Fc receptor, which triggers antibody-dependent cell-mediated cytotoxicity. Immunoediting of tumour cells by NK cells leads to tumour variants that can evade NK cell-mediated responses. Direct and indirect tumour escape mechanisms include secretion of immunosuppressive factors, shedding of ligands for the activating NK cell receptors and induction of ligands for activating NK cell receptors on healthy cells that can serve as decoys. Current checkpoint blockade agents used to activate T cells in cancer patients, such as antibodies against PD1, may also target NK cells. Checkpoint blockade targeting inhibitory receptors shared by NK cells and T cells are currently under clinical evaluation. In addition to engineered T cells, NK cells and their receptors represent an attractive alternative for the use of chimeric antigen receptors. Immunotherapeutic approaches such as the generation of bispecific linkers that engage activating NK cell receptors and tumour-specific antigens are also being developed to unleash the antitumour potential of NK cells. This Review discusses the role of natural killer (NK) cells in immunosurveillance of tumour cells, highlighting the new therapeutic approaches to NK cell targeting in the treatment of cancer and improvement of NK cell-mediated antitumour immune responses. Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.</description><subject>631/250/1619/382</subject><subject>631/67/1059/2325</subject><subject>631/67/327</subject><subject>Biomedicine</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Care and treatment</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune response</subject><subject>Killer cells</subject><subject>Killer Cells, Natural - physiology</subject><subject>Ligands</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - pathology</subject><subject>Neoplasms - therapy</subject><subject>Receptors, Natural Killer Cell - physiology</subject><subject>Regulation</subject><subject>review-article</subject><issn>1474-175X</issn><issn>1474-1768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqN0VtLBCEUB3CJovtLHyAGgohiN-86vUV0o6iXgt7EdbSdmtXSGaJvn8NusV0ewgdFf-fg4Q_AFoJDBIk89NEMMURsyBbAKqKCDpDgcvHrzB5WwFpKTxAijgRaBiuY85KWhK2Co5urwtimSYX2VWG0NzYeFe-h689Fa7UZF7X3urUz5u1b0cbaPKcNsOR0k-zmbF8H92endycXg-vb88uT4-uBYUi2g2okCcZVWXLsKiYYriQU1kHNJaFQOMegkNppyjWTDJWG0pGDBmpaYoOlI-tgb9r3JYbXzqZWTerUf0Z7G7qkkBBEEi5K_g_KUB6dQ5zpzg_6FLro8yBZcUEoxnROPerGqtq70EZt-qbqmJKScCQRy2r4h8qrspPaBG9dne-_FezOFYytbtpxCk3X1sGn73B_Ck0MKUXr1EusJzq-KwRVH77K4as-fNXj7dlI3Whiqy_6mXYGB1OQ8pN_tHFu5t_tPgDvBbKr</recordid><startdate>20160101</startdate><enddate>20160101</enddate><creator>Morvan, Maelig G.</creator><creator>Lanier, Lewis L.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20160101</creationdate><title>NK cells and cancer: you can teach innate cells new tricks</title><author>Morvan, Maelig G. ; Lanier, Lewis L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-db8322d9962fd5752d807ef0a683407ff5078afa46a58519c44bf0c0a492c28f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>631/250/1619/382</topic><topic>631/67/1059/2325</topic><topic>631/67/327</topic><topic>Biomedicine</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Care and treatment</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune response</topic><topic>Killer cells</topic><topic>Killer Cells, Natural - physiology</topic><topic>Ligands</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - pathology</topic><topic>Neoplasms - therapy</topic><topic>Receptors, Natural Killer Cell - physiology</topic><topic>Regulation</topic><topic>review-article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morvan, Maelig G.</creatorcontrib><creatorcontrib>Lanier, Lewis L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature reviews. Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morvan, Maelig G.</au><au>Lanier, Lewis L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NK cells and cancer: you can teach innate cells new tricks</atitle><jtitle>Nature reviews. Cancer</jtitle><stitle>Nat Rev Cancer</stitle><addtitle>Nat Rev Cancer</addtitle><date>2016-01-01</date><risdate>2016</risdate><volume>16</volume><issue>1</issue><spage>7</spage><epage>19</epage><pages>7-19</pages><issn>1474-175X</issn><eissn>1474-1768</eissn><abstract>Key Points Natural killer (NK) cells have a primordial role in tumour immunosurveillance. Given their potent antitumour activity, therapeutic manipulation of NK cells provides an attractive strategy for cancer treatment. A balance of inhibitory and stimulatory signals delivered by numerous receptors regulates NK cell functions (cytotoxicity, cytokine production and proliferation). NKG2D is the best characterized of these activating receptors and is directly involved in the recognition of tumours that express NKG2D ligands. NK cells detect and eliminate tumour cells that are deficient in major histocompatibility complex (MHC) class I molecules (missing self), have upregulated stress ligands that are recognized by activating NK cell receptors (induced self), or are coated with antibodies specific for tumour antigens, enabling recognition by NK cells expressing the CD16 Fc receptor, which triggers antibody-dependent cell-mediated cytotoxicity. Immunoediting of tumour cells by NK cells leads to tumour variants that can evade NK cell-mediated responses. Direct and indirect tumour escape mechanisms include secretion of immunosuppressive factors, shedding of ligands for the activating NK cell receptors and induction of ligands for activating NK cell receptors on healthy cells that can serve as decoys. Current checkpoint blockade agents used to activate T cells in cancer patients, such as antibodies against PD1, may also target NK cells. Checkpoint blockade targeting inhibitory receptors shared by NK cells and T cells are currently under clinical evaluation. In addition to engineered T cells, NK cells and their receptors represent an attractive alternative for the use of chimeric antigen receptors. Immunotherapeutic approaches such as the generation of bispecific linkers that engage activating NK cell receptors and tumour-specific antigens are also being developed to unleash the antitumour potential of NK cells. This Review discusses the role of natural killer (NK) cells in immunosurveillance of tumour cells, highlighting the new therapeutic approaches to NK cell targeting in the treatment of cancer and improvement of NK cell-mediated antitumour immune responses. Natural killer (NK) cells are the prototype innate lymphoid cells endowed with potent cytolytic function that provide host defence against microbial infection and tumours. Here, we review evidence for the role of NK cells in immune surveillance against cancer and highlight new therapeutic approaches for targeting NK cells in the treatment of cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>26694935</pmid><doi>10.1038/nrc.2015.5</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1474-175X
ispartof Nature reviews. Cancer, 2016-01, Vol.16 (1), p.7-19
issn 1474-175X
1474-1768
language eng
recordid cdi_proquest_miscellaneous_1773836796
source MEDLINE; Nature Journals Online; SpringerLink Journals - AutoHoldings
subjects 631/250/1619/382
631/67/1059/2325
631/67/327
Biomedicine
Cancer
Cancer Research
Care and treatment
Health aspects
Humans
Immune response
Killer cells
Killer Cells, Natural - physiology
Ligands
Neoplasms - immunology
Neoplasms - pathology
Neoplasms - therapy
Receptors, Natural Killer Cell - physiology
Regulation
review-article
title NK cells and cancer: you can teach innate cells new tricks
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T05%3A19%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NK%20cells%20and%20cancer:%20you%20can%20teach%20innate%20cells%20new%20tricks&rft.jtitle=Nature%20reviews.%20Cancer&rft.au=Morvan,%20Maelig%20G.&rft.date=2016-01-01&rft.volume=16&rft.issue=1&rft.spage=7&rft.epage=19&rft.pages=7-19&rft.issn=1474-175X&rft.eissn=1474-1768&rft_id=info:doi/10.1038/nrc.2015.5&rft_dat=%3Cgale_proqu%3EA439361815%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1767342242&rft_id=info:pmid/26694935&rft_galeid=A439361815&rfr_iscdi=true